BioNTech SE (BNTX) has released an update.
The FDA has lifted the partial clinical hold on BioNTech and MediLink’s Phase I trial of BNT326/YL202, a promising cancer treatment targeting HER3. After addressing safety concerns related to dose-dependent adverse events, the trial will proceed focusing on safer dose levels with manageable side effects. This development marks a significant step for BioNTech in advancing its oncology portfolio and commitment to patient safety.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
